Abstract 20P
Background
In China, new breast cancer (BC) patients (pts) in county regions (including rural areas) account for more than 40% of all BC cases each year. No studies have reported the disease characteristics and treatment patterns of BC pts in China counties. This study aimed to explore the treatment patterns of BC pts in county-level hospitals in China.
Methods
CHASE001 was an observational, multicenter study assessing real-world treatment patterns among pts with HER2+ or HR+/HER2- BC conducted at 26 sites in county areas of China, including four cohorts (HER2+ early BC (eBC), HR+/HER2- eBC, HER2+ advanced BC (aBC), and HR+/HER2- aBC). The primary endpoint was treatment patterns within each cohort. The interim results for HER2+ eBC and HR+/HER2- eBC are described here.
Results
628 pts were included (302 in HER2+ eBC and 326 in HR+/HER2- eBC cohort): for HER2+ and HR+/HER2- cohort respectively, median age, 53/51 years; clinical T2, 41.39%/37.73%; clinical N0, 41.72%/45.40%. Of 584 pts who underwent breast cancer surgery, only 10.53% (30/285) received breast-conserving surgery (BCS) in HER2+ and 12.71% (38/299) in HR+/HER2- cohort. Notably, the proportions of adjuvant radiotherapy (RT) following BCS were 46.67% (14/30) in HER2+ and 47.37% (18/38) in HR+/HER2- cohort. In HER2+ cohort, 20.20% (61/302) received neoadjuvant therapy (NAT) while 94.70% (286/302) received adjuvant therapy. 81.97% (50/61) of NAT were HER2 targeted regimens, of which 84.00% (42/50) received dual anti-HER2 target therapy (trastuzumab/pertuzumab). 80.77% (231/286) of adjuvant therapies were HER2 targeted regimens, of which 53.68% (124/231) were dual-targeted. Of pts with positive lymph nodes who received HER2 targeted adjuvant therapy, 75.90% applied dual anti-HER2 target therapy. In HR+/HER2- cohort, 13.50% (44/326) received NAT while 92.02% (300/326) received adjuvant therapy. The most common neoadjuvant and adjuvant chemotherapy regimens were both AC-T (41.67% and 51.79%, respectively).
Conclusions
This analysis showed unsatisfactory adherence to guidelines for BCS, RT, and NAT, but higher adherence for adjuvant anti-HER2 therapy. Further action was needed to ensure that patients in Chinese county had access to high quality and guideline centric care.
Clinical trial identification
NCT05544123.
Editorial acknowledgement
Legal entity responsible for the study
P. Lu.
Funding
AstraZeneca.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy
Presenter: Wenhua Li
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract